FDA approves Mercay Weight PD-1 inhibitor favipiravir

today, the(http:// of theof MSD announcedthat the U.Sthe FDA's(http://accelerate the approval of the company's heavy-duty PD-1 inhibitorsAccording to a recent study, researchers at the University of Washington's StLouis School of Medicine have discovered an experimental antiviraldrug,(http://that can treat mice infected with the Bourbon virusthe drug, called favipiravir, had previously been approved in Japan but had not been approved in the United States for the treatment of the diseaseIn another experiment, the researchers treated infected mice with flu drugs or a placebo for eight daysWhen the mice were infected with the virus at the same time or within a day, all the mice survived withno apparent symptoms, in contrast, none of the infected mice who received a placebo survivedWhen the researchers were treated with antivirals three days after the infection, all the mice treated recovered 　　Keytruda, an anti-PD-1 therapy developed by Mercado, is a heavy drug in the field of immunocheckpoint inhibitors It improves the body's immune system's ability to detect and attack tumor cells by suppressing the immune suppression signals mediated by PD-1 receptors The heavy-weight therapy has been expanding its indications since it first received FDA approval in 2014 to treat advanced melanoma is more effective in the field of lung cancer, has been approved by a number of FDA, as a combination of therapy or single-drug therapy, first-line treatment Of NSCLC 　　This approval is based primarily on Keytruda's performance in Phase 2 Clinical Trial (http:// (n-64) and KEYNOTE-28 In Phase 1b Clinical Trials (n-19) patients who had received more than two pre-treatments in both trials, but whose disease continued to progress, were treated with Keytruda analysis (http:// showed that Keytruda's overall remission rate was 19.3 percent, with 2 patients achieving full remission and 14 patients achieving partial remission More than half of the patients who received the remission lasted more than 18 months